SCHEMBL18264263

SCHEMBL18264263

COc1ccc([C@H]2COC[C@@H]2C(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
KDM1A O60341 2/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
EDNRA P25101 2/20 0.44
EDNRB P24530 1/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18264207 1.00 FPR2 (0.49) FPR2L3MBTL1KDM1AMAOAMAOB
SCHEMBL20411436 1.00 FPR2 (0.49) FPR2L3MBTL1KDM1AMAOAMAOB
SCHEMBL22097655 1.00 FPR2 (0.49) FPR2L3MBTL1KDM1AMAOAMAOB
SCHEMBL18264209 1.00 FPR2 (0.49) FPR2L3MBTL1KDM1AMAOAMAOB
SCHEMBL18264211 1.00 FPR2 (0.49) FPR2L3MBTL1KDM1AMAOAMAOB
SCHEMBL20411416 0.86 FPR2 (0.51) FPR2KDM1AMAOAMAOBRAB9A
SCHEMBL28523929 0.86 FPR2 (0.51) FPR2KDM1AMAOAMAOBRAB9A
SCHEMBL10289077 0.80 RAB9A (0.57) L3MBTL1KDM1AMAOAMAOBEDNRA
SCHEMBL432751 0.80 RAB9A (0.57) L3MBTL1KDM1AMAOAMAOBEDNRA
SCHEMBL18596476 0.80 RAB9A (0.57) L3MBTL1KDM1AMAOAMAOBEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3331884-B1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN SEIYAKU KK (JP) 2020-06-17 EP disclosed
US-20180207153-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN PHARMACEUTICAL CO., LTD. (JP) 2018-07-26 US disclosed
EP-3331884-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kyorin Pharmaceutical Co., Ltd. (JP) 2018-06-13 EP disclosed
WO-2016189876-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180207153-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF FPR1, FPR2, SAAL1 FPR2 2/4885L3MBTL1 1995/4885KDM1A 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.